循環器ジャーナル72巻2号

2024年04月発行

特集 心エコー　何をどこまで評価できるか？ Ⅱ. 心エコーを活かして心不全を治療する

がん治療に関連する心筋障害　心エコーでどうマネジメントする？

著者： 戸次宣史¹ 志賀太郎¹

所属機関： ¹がん研究会有明病院腫瘍循環器・循環器内科

ページ範囲：P.267 - P.273

POINT
・がんと心血管疾患の合併が増えており，腫瘍循環器学の重要性が高まっている．
・心エコーにより心毒性を早期に検出することが大切である．
・心毒性の早期発見，早期治療介入が患者に大きなメリットをもたらす．

参考文献

1）Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines : The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology（ESC）. Eur Heart J 2016 ; 37 : 2768-2801.

2）Shiga T, Hiraide M. Cardiotoxicities of 5-Fluorouracil and Other Fluoropyrimidines. Curr Treat Options Oncol 2020 ; 21 : 27.

3）小室一成（監）．日本腫瘍循環器学会編集委員会（編）．腫瘍循環器診療ハンドブック．メジカルビュー社，2020

4）Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment : ESMO consensus recommendations. Ann Oncol 2020 ; 31 : 171-90.

5）Gent DG, Rebecca D. The 2022 European Society of Cardiology Cardio-oncology Guidelines in Focus. Eur Cardiol 2023 ; 18 : e16.

6）Raber I, Asnani A. Cardioprotection in cancer therapy : novel insights with anthracyclines. Cardiovasc Res 2019 ; 115 : 915-21.

7）Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 2012 ; 18 : 1639-42.

8）Pommier Y, Leo E, Zhang H, et al. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 2010 ; 17 : 421-33.

9）Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction : time to recognize a new entity. J Clin Oncol 2005 ; 23 : 2900-2.

10）Lenneman CG, Sawyer DB. Cardio-oncology : an update on cardiotoxicity of cancer-related treatment. Circ Res 2016 ; 118 : 1008-20.

11）Oka T, Akazawa H, Naito AT, et al. Angiogenesis and cardiac hypertrophy : maintenance of cardiac function and causative roles in heart failure. Circ Res 2014 ; 114 : 565-71.

12）Salem JE, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors : an observational, retrospective, pharmacovigilance study. Lancet Oncol 2018 : 1579-89.

13）Armenian SH, Lacchetti C, Barac A, et al. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers : American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2017 ; 35 : 893-911.

14）野中顕子（監），日本心エコー図学会 ガイドライン委員会（編）．抗がん剤治療関連心筋障害の診療における心エコー図検査の手引，2020

15）Thavendiranathan P, Negishi T, Somerset E, et al. Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy. J Am Coll Cardiol. 2021 ; 77 : 392-401.

16）日本臨床腫瘍学会・日本腫瘍循環器学会（編）．Onco-cardiologyガイドライン，南江堂，2023

17）Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure : A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 ; 145 : e895-e1032.